Apimeds Pharmaceuticals US, Inc. (APUS) Financial Statements
Apimeds Pharmaceuticals US, Inc. Financial Overview
Apimeds Pharmaceuticals US, Inc.'s market cap is currently $4.54M. The company's EPS TTM is $-49.29; its P/E ratio is -0.06; Apimeds Pharmaceuticals US, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -5.71K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -11.91M | $ -1.28M | $ -747.44K | $ -639.53K | $ -1.02M |
| EBITDA | $ -5.71M | $ -1.27M | $ -739.63K | $ -639.53K | $ -1.02M |
| Net Income | $ -6.00M | $ -1.39M | $ -777.69K | $ -668.67K | $ -1.03M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.64M | $ 3.46K | $ 410.48K | $ 6.17K | $ 171.44K |
| Total Assets | $ 164.18M | $ 13.06K | $ 422.08K | $ 6.17K | $ 172.17K |
| Total Debt | $ 7.76M | $ 596.84K | $ 266.89K | $ 660.00K | $ 400.00K |
| Net Debt | $ 6.12M | $ 593.39K | $ -143.59K | $ 653.83K | $ 228.56K |
| Total Liabilities | $ 10.84M | $ 1.37M | $ 390.20K | $ 719.78K | $ 410.65K |
| Stockholders' Equity | $ 153.35M | $ -1.36M | $ 31.87K | $ -713.61K | $ -238.48K |
| Cash Flow | |||||
| Free Cash Flow | $ -8.98M | $ -733.53K | $ -627.79K | $ -448.17K | $ -823.11K |
| Operating Cash Flow | $ -8.93M | $ -733.53K | $ -627.79K | $ -448.17K | $ -823.11K |
| Investing Cash Flow | $ -10.06M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 20.62M | $ 326.50K | $ 1.03M | $ 282.90K | $ 400.00K |
Currency in USD